On March 15th, Securities Daily News reported that BeiGene announced that the company has recently learned that the US Food and Drug Administration (FDA) has approved the company's core product, Teralizumab (Chinese product name: Bazean; English product name: TEVIMBRA), as a monotherapy for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after previous systemic chemotherapy (excluding PD-1/L1 inhibitors) Adult patients.